Abstract

Researchers at Seoul National University Bundang and Children’s Hospitals, Republic of Korea evaluated the long-term effectiveness and tolerability of ethosuximide (ESX), valproic acid (VPA), and lamotrigine (LTG) as initial monotherapies for patients with childhood absence epilepsy (CAE).

Highlights

  • CELIAC DISEASE AND INCREASED RISK OF EPILEPSY

  • Researchers at Orebro University Hospital, Orebro, and the Karolinska Institute, Stockholm, Sweden; and the Universities of Naples and Salerno, Italy examined the risk of developing epilepsy in a nationwide population-based sample of >28,000 patients with biopsy-verified celiac disease (CD)

  • Celiac disease carries a moderately increased risk of epilepsy, and patients with epilepsy are at increased risk of future CD

Read more

Summary

Introduction

CELIAC DISEASE AND INCREASED RISK OF EPILEPSY Researchers at Orebro University Hospital, Orebro, and the Karolinska Institute, Stockholm, Sweden; and the Universities of Naples and Salerno, Italy examined the risk of developing epilepsy in a nationwide population-based sample of >28,000 patients with biopsy-verified celiac disease (CD). In those patients with epilepsy treated with AEDs, the increased risk of epilepsy was 1.43.

Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.